Tokyo, Japan, Aug 4, 2005 - (JCNN) - Taisho Pharmaceutical (TSE: 4535) announced on August 3 that it has received approval from the Ministry of Health, Labor and Welfare for an OTC-switched version of Zaditen Nasal Solution, an antiallergic agent developed by Novartis Pharma.
Taisho will distribute OTC-switched Zaditen as its Pabron series through pharmacies across Japan while Novartis Pharma will import it.
Containing ketotifen fumarate as a main ingredient, the product helps alleviate nasal allergy symptoms due to pollen and house-dust mites.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group